Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The target concentration approach to clinical drug development.

Literature DB >> 8582116

The target concentration approach to clinical drug development.

N H Holford¹.

Abstract

Mesh：

Year: 1995 PMID： 8582116 DOI： 10.2165/00003088-199529050-00001

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

11 in total

1. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Authors: C C Peck; W H Barr; L Z Benet; J Collins; R E Desjardins; D E Furst; J G Harter; G Levy; T Ludden; J H Rodman
Journal: Clin Pharmacol Ther Date: 1992-04 Impact factor: 6.875

2. The intellectual health of clinical drug evaluation.

Authors: L B Sheiner
Journal: Clin Pharmacol Ther Date: 1991-07 Impact factor: 6.875

3. Pharmacologically guided phase I clinical trials based upon preclinical drug development.

Authors: J M Collins; C K Grieshaber; B A Chabner
Journal: J Natl Cancer Inst Date: 1990-08-15 Impact factor: 13.506

4. Concentration-controlled versus concentration-defined clinical trials.

Authors: G Levy
Journal: Clin Pharmacol Ther Date: 1993-03 Impact factor: 6.875

5. Comparative efficiencies of randomized concentration- and dose-controlled clinical trials.

Authors: L Endrenyi; J Zha
Journal: Clin Pharmacol Ther Date: 1994-09 Impact factor: 6.875

6. Concentration- or effect-controlled clinical trials with sparse data.

Authors: G Levy; W F Ebling; A Forrest
Journal: Clin Pharmacol Ther Date: 1994-07 Impact factor: 6.875

7. Population pharmacodynamics of romazarit.

Authors: N H Holford; P E Williams; G J Muirhead; A Mitchell; A York
Journal: Br J Clin Pharmacol Date: 1995-03 Impact factor: 4.335

8. Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline.

Authors: S Vozeh; G Kewitz; A Perruchoud; M Tschan; C Kopp; M Heitz; F Follath
Journal: Am Rev Respir Dis Date: 1982-02

9. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial.

Authors: N Holford; Y Hashimoto; L B Sheiner
Journal: Clin Pharmacokinet Date: 1993-12 Impact factor: 6.447

10. Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial.

Authors: N Holford; P Black; R Couch; J Kennedy; R Briant
Journal: Clin Pharmacokinet Date: 1993-12 Impact factor: 6.447

15 in total

Review 10. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.

Authors: Ralph E Parchment; James H Doroshow
Journal: Semin Oncol Date: 2016-07-26 Impact factor: 4.929

The target concentration approach to clinical drug development.

1. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

2. The intellectual health of clinical drug evaluation.

3. Pharmacologically guided phase I clinical trials based upon preclinical drug development.

4. Concentration-controlled versus concentration-defined clinical trials.

5. Comparative efficiencies of randomized concentration- and dose-controlled clinical trials.

6. Concentration- or effect-controlled clinical trials with sparse data.

7. Population pharmacodynamics of romazarit.

8. Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline.

9. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial.

10. Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial.

1. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

2. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children.

Review 3. Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Review 4. Prediction of exposure-response relationships to support first-in-human study design.

Review 5. Integrated pharmacokinetics and pharmacodynamics in drug development.

6. Drug distribution. The forgotten relative in clinical pharmacokinetics.

7. Validation of a decision support system for use in drug development: pharmacokinetic data.

Review 8. Target concentration strategy for cyclosporin monitoring.

9. A Bayesian dose-individualization method for warfarin.

Review 10. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.